Fig. 5.
Extent of (A) cluster of differentiation (CD)−4+ and (B) CD16+ T-cell infiltration in tumor biopsies at baseline and during treatment (day 29) with vanucizumab for patients with a documented best overall response of progressive disease (PD) or stable disease (SD)a. aNon-paired data points are shown for completeness where data points are missing.